Better Buy: Johnson & Johnson vs. Pfizer
They're two of the oldest, largest, and most respected healthcare companies around. But one has made investors much happier than the other in recent years. Johnson & Johnson (NYSE: JNJ) stock is up more than twice as much as Pfizer (NYSE: PFE) stock over the past five years, and it's a similar story so far in 2017.
That's looking in the rearview mirror, though. Which of these healthcare stocks is the better choice for long-term investors now? Here's how Johnson & Johnson and Pfizer compare.
Image source:Getty Images.
Source: Fool.com
Johnson & Johnson Aktie
224,25 €
0,11 %
Die Community ist sich einig: Johnson & Johnson nur mit Buy-Einschätzungen, keine Sell-Einschätzungen.
Das Kursziel von 228 € für Johnson & Johnson impliziert eine leichte Steigerung gegenüber dem aktuellen Kurs von 224.25 €.
